News stories about Affimed (NASDAQ:AFMD) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Affimed earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.5839978959495 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of AFMD traded down $0.03 during midday trading on Thursday, reaching $1.80. The stock had a trading volume of 132,100 shares, compared to its average volume of 613,662. Affimed has a 52 week low of $1.15 and a 52 week high of $2.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 5.57 and a current ratio of 5.60. The company has a market capitalization of $112.30 million, a PE ratio of -2.31 and a beta of 2.33.
Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.18) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.18). Affimed had a negative return on equity of 90.64% and a negative net margin of 1,429.80%. The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.54 million. equities research analysts forecast that Affimed will post -0.68 EPS for the current fiscal year.
A number of research firms have recently commented on AFMD. ValuEngine raised Affimed from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Zacks Investment Research raised Affimed from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Thursday, March 29th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $3.92.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.